RFCA
ACOR

R&F Capital Advisors’s Acorda Therapeutics ACOR Stock Holding History

R&F Capital Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$240K Buy
+95
New +$273K 0.06% 484

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

R&F Capital Advisors's ACOR Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Acorda Therapeutics (ACOR) in Q1 2017: 95 shares worth $240K. The stake represents 0.06% of the portfolio and ranks #484 among its holdings.

178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • R&F Capital Advisors held 95 shares of Acorda Therapeutics worth $240K as of Q1 2017.
  • Acorda Therapeutics was a new R&F Capital Advisors position in Q1 2017.
  • Acorda Therapeutics made up 0.06% of R&F Capital Advisors's portfolio in Q1 2017, its #484 holding.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.